Angiotensin-converting Enzyme 2-containing Small Extracellular Vesicles and Exomeres Bind the Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein.

There is an increasing appreciation for the role of secreted extracellular vesicles (EVs) and nonvesicular nanoparticles in both physiologic and pathophysiologic conditions. Small EVs (sEVs) are 40- to 200-nm lipid-bilayer enclosed membrane vesicles, whereas exomeres are small (<50 nm), nonmembranous, extracellular nanoparticles. , The coronavirus disease 2019 (COVID-19) pandemic is caused by the recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For infection, SARS-CoV-2 must bind to the host cell receptor angiotensin-converting enzyme 2 (ACE2) to gain entry. ACE2 is also the critical receptor used by SARS-CoV-1, responsible for the 2002–2004 SARS epidemic. Middle East respiratory syndrome (MERS) is a highly lethal respiratory disease initiated by binding of MERS-CoV to its entry receptor dipeptidyl peptidase 4 (DPP4). ACE2 and DPP4 are highly expressed in gastrointestinal tissues, and a significant number of COVID-19, SARS, and MERS patients present with gastrointestinal symptoms. , The ectodomain of ACE2 can be released by the activity of tumor necrosis factor-α converting enzyme (TACE) and the transmembrane serine protease 2 (TMPRSS2). The S1 subunit of the spike (S) protein of SARS-CoV-2 is primed by TMPRSS2 or TMPRSS4 for cell entry , , and TMPRSS2 can also prime the S protein of MERS-CoV.

It has been demonstrated that human recombinant soluble ACE2, but not mouse ACE2, can inhibit SARS-CoV-2 infection, raising the possibility that extracellular ACE2 carried by sEVs or extracellular nanoparticles may act as a decoy to bind the virus. Here, we explore the hypothesis that sEVs and exomeres containing ACE2 can bind SARS-CoV-2.

Methods

Detailed methods are available in the Supplementary Methods.

Results

Colorectal cancer cell lines LIM1215 and DiFi express high levels of ACE2, whereas Caco-2 express much less, and ACE2 was undetectable in DKO-1 (Figure 1 A). After high-resolution density gradient purification, ACE2 was found to be secreted in LIM1215 and DiFi sEVs, whereas DPP4 was enriched in sEVs from LIM1215, DiFi, and DKO-1 cells (Figure 1 A and Supplementary Figure 1 B). The proteases TACE, TMPRSS2, and TMPRSS4 were all expressed by LIM1215, DiFi, and DKO-1 cells and secreted in sEVs (Figure 1 A and Supplementary Figure 1 A).

Figure 1

sEVs and exomeres containing ACE2 can bind SARS-CoV-2 through the virus spike (S) protein. (A) Immunoblot analysis of cells and sEVs purified by high-resolution density gradients. (B) LIM1215 (left) and DiFi (right) samples were fractionated followed by immunoblotting. Arrow, full-length ACE2; ∗Ectodomain glycoform 1 of ACE2; ∗∗Ectodomain glycoform 2 of ACE2; ACE2 (ecto), ectodomain-specific monoclonal antibody; ACE2 (intra), intracellular-specific monoclonal antibody; I, glycosylated DPP4; II, nonglycosylated DPP4; anti-CD63 and anti-HSPA13 are used as exosomal and exomere markers, respectively; NV, nonvesicular; Exom, exomere. (C) Fluorescence-activated vesicle sorting analysis for ACE2 expression in sEV pellets (P) and exomeres from DiFi cells using an ectodomain-specific polyclonal antibody directly conjugated to PE. (D) Immunoblot analysis of inducible nitric oxide synthase (iNOS) and ACE2 expression in LIM1215 cells treated with indicated doses of interferon gamma (INF-γ) and TNF-α. (E) Sample inputs from DiFi cells (left) and agarose-conjugated Sambucus nigra agglutinin (SNA) lectin pull-downs (right) were analyzed by immunoblotting. β1-Integrin and epidermal growth factor receptor (EGFR) are known to be α2,6-sialylated and were used as positive controls. (F) Binding of human recombinant soluble ACE2 to the RBD of SARS-CoV-2 S protein. IP, immunoprecipitation; IB, immunoblotting. (G) Binding of DiFi exomeres with RBD of SARS-CoV-2 S protein. (H) Binding of DiFi cells, sEV-P, and exomeres with the S1 subunit of SARS-CoV-2 S protein. (I) Fluorescence-activated vesicle sorting analysis for binding of DiFi sEV-P and exomere to a mouse Fc-tagged RBD of SARS-CoV-2 S protein. (J) Schematic illustration of (i) SARS-CoV-2 viral infection of ACE2-positive cells and (ii) inhibition of infection due to hypothetical viral decoy binding by ACE2-positive sEVs and exomeres. Similarly, DPP4-positive sEVs and exomeres may act as decoys for MERS-CoV.

Supplementary Figure 1

(A) Immunoblot analysis of colorectal cancer cells with indicated antibodies. (B) Immunoblot analysis of DKO-1 cells, sEV, and nonvesicular (NV) samples with indicated antibodies. (C) Fluorescence-activated vesicle sorting analysis for ACE2 expression in DiFi sEV-P using an ectodomain-specific monoclonal ACE2 primary antibody followed by an Alexa-647 secondary antibody. ß-actin serves as a loading control.

To investigate further, we fractionated extracellular samples into sEV, nonvesicular, and exomere fractions. , Although cells and sEVs contained full-length ACE2, the 2 ectodomain glycoforms of ACE2 were present in exomeres (Figure 1 B). The full-length ACE2 in cells and sEVs was detected with antibodies recognizing ectodomain and intracellular epitopes. However, the 2 shed ectodomain fragments present in exomeres were only detected with the ectodomain-specific ACE2 antibody, confirming identity (Figure 1 B). Additionally, full-length DPP4 was highly enriched in sEVs from both LIM1215 and DIFI cells, whereas shed ectodomain DPP4 was present in exomeres (Figure 1 B). Both DiFi cell-derived ACE2-containing sEVs and exomeres could be analyzed using fluorescence-activated vesicle sorting with a polyclonal antibody recognizing the ectodomain of ACE2 (Figure 1 C). Fluorescence-activated vesicle sorting detection of sEVs was confirmed by using a monoclonal antibody to the ectodomain of ACE2 (Supplementary Figure 1 C).

Because inflammatory cytokines modulate expression of ACE2 and inflammation influences ACE2 messenger RNA levels in ileal and colonic tissue, we sought to determine the baseline inflammatory state of colorectal cancer cells secreting sEV- and exomere-containing ACE2. Under the growth conditions used for production of sEVs and exomeres, levels of the inflammatory marker, inducible nitric oxide synthase, were clearly detectable in Caco-2 cells but were undetectable in DLD-1, LIM1215, and DiFi cells (Supplementary Figure 2 A). ACE2 levels were high in DiFi and LIM1215 cells but were much lower in Caco-2 and undetectable in DLD-1 cells. However, after treatment with the inflammatory cytokine, interferon gamma, or co-treatments with interferon gamma and TNF-α, the expression of inducible nitric oxide synthase was strongly induced in both LIM1215 and DiFi cells (Figure 1 D and Supplementary Figure 2 B). Furthermore, these inflammatory cytokines significantly reduced ACE2 protein levels in both LIM1215 and DiFi cells, whereas ACE2 levels in Caco-2 cells were relatively unchanged (Figure 1 D and Supplementary Figure 2 B). Thus, under these culture conditions, LIM1215 and DiFi cells were in a noninflammatory state at baseline, but interferon gamma in particular decreased cellular levels of ACE2.

Supplementary Figure 2

(A) Immunoblot analysis of inducible nitric oxide synthase (iNOS) and ACE2 expression in cells cultured under standard conditions for EV and exomere isolation. (B) Immunoblot analysis of iNOS and ACE2 expression in cells treated with indicated concentrations of interferon gamma (INF-γ) and TNF-α. (C) Immunoblot analysis for ACE2 from LS174T cells, sEV-Ps, and Exom. (D) Fluorescence-activated vesicle sorting analysis of LS174T, sEV-Ps, and exomeres binding to a mouse Fc-tagged RBD of SARS-CoV-2 spike protein S1. Actin serves as a loading control.

ACE2 and DPP4 are type I and type II transmembrane receptors, respectively, and both are known to be extensively glycosylated in their respective N-terminal or C-terminal ectodomains. The enzyme responsible for α2,6-sialylation, β-galactoside α2,6-sialyltransferase 1, was enriched in DiFi exomeres (Figure 1 E, left). We isolated total α2,6-sialylated proteins by Sambucus nigra agglutinin lectin pull-down and probed for ACE2 by immunoblotting. Full-length ACE2 in cells and sEVs was modified by α2,6-sialylation, as were the 2 ectodomain glycoforms secreted in exomeres (Figure 1 E, right).

Virus-receptor recognition occurs through the receptor-binding domain (RBD) of the S glycoprotein of SARS-CoV-2 with the extracellular peptidase of the ACE2 ectodomain. Because the RBD of the SARS-CoV-2 S protein subunit S1 binds the ectodomain of ACE2, the presence of the ectodomain of ACE2 in exomeres suggested these extracellular nanoparticles might bind the virus. We first confirmed a mouse Fc-tagged RBD of the S1 subunit could bind human recombinant soluble ACE2 (Figure 1 F). We next demonstrated that DiFi exomeres containing ACE2 could be bound and pulled down with the mouse Fc-tagged RBD (Figure 1 G). Moreover, S1 subunit could bind DiFi cells, sEVs, and exomeres that all contain ACE2 (Figure 1 H). Fluorescence-activated vesicle sorting analysis further confirmed that ACE2-positive DiFi sEVs and exomeres could bind to the RBD (Figure 1 I), whereas sEVs and exomeres from the ACE2-negative LS174T cell line could not (Supplementary Figure 2 C and D). It has been demonstrated that human soluble recombinant ACE2 can act as a decoy for SARS-CoV-2 and thereby inhibit infection. Based on our characterization of extracellular carriers of ACE2 and their binding to SARS-CoV-2 S protein, we propose that ACE2-containing sEVs and exomeres may also act as decoys to inhibit infection (Figure 1 J).

Discussion

We showed that full-length ACE2 and DPP4, critical receptors for SARS-CoV-1, SARS-CoV-2, and MERS-CoV, are released in sEVs from colorectal cancer cells and that shed ectodomain fragments of ACE2 and DPP4 are enriched in exomeres. To our knowledge, we provide the first evidence that ACE2 in cells, sEVs, and exomeres is α2,6-sialylated. Both sEVs and exomeres released from cells expressing ACE2 can bind to the RBD of the SARS-CoV-2 S protein S1 subunit. Thus, human cells might be used for large-scale production of EVs and exomeres containing fully post-translationally modified ACE2 that can be used as decoys for SARS-CoV-2 to attenuate infection, as has been demonstrated for human soluble recombinant ACE2. Studies comparing the efficiency and stability of S protein binding between recombinant soluble ACE2, sEVs containing full-length ACE2, and exomeres containing ectodomain ACE2 may inform the best therapeutic intervention for COVID-19 infections. The inflammatory state of gastrointestinal tissues can influence the expression of ACE2. Intriguingly, we find that induction of inflammation can lead to a marked reduction of ACE2 protein expression in LIM1215 and DiFi colorectal cancer cells. Further study is necessary to determine if inflammatory modulation of cellular ACE2 expression results in altered secretion of ACE2-containing sEVs and exomeres. It is possible that inflammation leads to increased secretion of ACE2 in sEVs and exomeres, thereby lowering cellular levels, or that lower cellular levels result in decreased release of ACE2. In either case, the inflammatory state of tissues may influence the proposed decoy effect of extracellular ACE2.

To enable binding to ACE2, TMPRSS2 or TMPRSS4 prime the SARS-CoV-2 S protein. Additionally, the proteases TNF-α converting enzyme and TMPRSS2 cleave ACE2 to release the ectodomain. Thus, the activity of these proteases is critical for infection, and these proteins may represent important clinical targets. We found that TMPRSS2, TMPRSS4, and TNF-α converting enzyme are all secreted in sEVs and are thus present in the extracellular environment, allowing them to potentially interact with viral particles. It is currently unknown if the sEV-embedded proteases play any role in priming of coronavirus S proteins or if transfer of these proteases to recipient cells can prime cells for subsequent virus entry into host cells. Our findings have potential important implications for COVID-19, SARS, and MERS.